The story of Ozempic isn’t just about weight loss; it’s about how a miracle drug becomes a monopoly, how policy paralysis lets corporations dictate dosage, and how everyday Australians will end up footing the bill for another avoidable health-care scandal.
When government inaction and corporate greed collide, the prescription pad catches fire It’s already happened once in America — and if Canberra’s asleep at the wheel (again), it’ll happen here next.
The Drug That Ate the World
Ozempic (semaglutide) is the latest darling of Big Pharma — a once-a-week injection that suppresses appetite and helps diabetics control blood sugar. Used carefully, it can change lives. But in the U.S., the rollout has turned into a feeding frenzy, with patients pushed onto higher doses too fast, clinics rewarded for aggressive prescribing, and lower-dose starter pens conveniently “out of stock.”
Why? Because the lower doses make less money.
Compounding pharmacies that tried to fill the gap were swiftly targeted by corporate lawyers and regulators after the big manufacturers — Eli Lilly and Novo Nordisk — lobbied to end emergency exemptions allowing local production. With that loophole closed, two multinationals now control the entire American GLP-1 supply chain, dictating availability, pricing, and access.
Sound familiar? It should. We’ve seen this playbook before — in energy, in housing, in tobacco. When Canberra moves too slowly, monopolies move first.
Australia’s Supply Squeeze Has Already Begun
Here at home, pharmacies are already warning of intermittent shortages, off-label use, and prescribing confusion as demand skyrockets. Doctors are seeing patients source Ozempic through online “tele-clinics,” sometimes with no diabetes diagnosis at all.
Meanwhile, the Therapeutic Goods Administration (TGA) and Health Department continue to sit on the fence — issuing mild guidance while pretending this is a passing fad. But the numbers don’t lie: private clinics, celebrity endorsements, and TikTok influencers have done what public health couldn’t — made weekly injections the new lifestyle accessory.
If Australia doesn’t put proper dosage controls, prescriber training, and domestic supply transparency in place now, we’ll be next in line for the same “dose distortion” the U.S. is already paying for.
The Monopolisation Playbook Has Landed
Here’s what’s coming if Canberra blinks:
1️⃣ Patent lock-ins — Reclassification of these drugs as “biologics,” which would grant Big Pharma twelve-year monopolies.
2️⃣ Supply manipulation — Prioritising high-dose, high-profit pens while claiming “shortages” of starter doses.
3️⃣ Regulatory capture — Lobbyists whispering to departments that “compounding is unsafe,” sidelining local pharmacists and smaller biotech firms.
4️⃣ Telehealth takeover — The same companies suing independent telehealth providers in the U.S. are quietly launching their own Australian online platforms.
Unless Canberra learns from America’s mistake, the same system that over-prescribed opioids and under-delivered accountability will repeat itself — only this time, it’ll come with hashtags and celebrity sponsorships.
The Hollow Centre Warning
If government treats Ozempic as just another fad drug, it will become another long-term economic and health crisis. We’ll see Australians trapped between unaffordable prescriptions and unsafe knock-offs, while Canberra pats itself on the back for “world-leading regulation.”
Because when regulation lags behind innovation, it isn’t regulation — it’s permission.
This isn’t about whether Ozempic works. It’s about who it works for. And right now, every sign points to Big Pharma, not the patient.
– The Hollow Centre
